Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Belite Bio, Inc. ADR ( (BLTE) ) has shared an announcement.
On July 2, 2025, Belite Bio announced the completion of enrollment in their global Phase 3 PHOENIX trial, which is evaluating the safety and efficacy of Tinlarebant for Geographic Atrophy (GA) in dry age-related macular degeneration (AMD). This milestone marks significant progress in the development of Tinlarebant, a potential oral treatment for GA, a condition with no current approved oral therapies. The trial, which enrolled 500 subjects across multiple countries, aims to assess Tinlarebant’s ability to slow the growth of atrophic lesions, a key marker of disease progression. The completion of enrollment underscores the global interest in this investigational therapy and highlights the unmet need for effective GA treatments.
The most recent analyst rating on (BLTE) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Belite Bio, Inc. ADR stock, see the BLTE Stock Forecast page.
Spark’s Take on BLTE Stock
According to Spark, TipRanks’ AI Analyst, BLTE is a Neutral.
Belite Bio faces significant financial challenges with no revenue and increasing losses, impacting its overall score. Technical indicators show neutral momentum, and valuation is unattractive with negative earnings. However, the earnings call highlights clinical advancements and financial stability, providing a positive outlook in the long term despite current financial difficulties.
To see Spark’s full report on BLTE stock, click here.
More about Belite Bio, Inc. ADR
Belite Bio is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for degenerative retinal diseases with significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), as well as specific metabolic diseases. Their lead candidate, Tinlarebant, is an oral therapy aimed at reducing toxin accumulation in the eye and is currently under evaluation in various clinical trials.
Average Trading Volume: 36,015
Technical Sentiment Signal: Buy
Current Market Cap: $1.86B
Learn more about BLTE stock on TipRanks’ Stock Analysis page.